Cargando…

CD7-deleted hematopoietic stem cells can restore immunity after CAR T cell therapy

Targeting T cell malignancies with universal CD7-targeting chimeric antigen receptor T cells (UCART7) can lead to profound immune deficiency due to loss of normal T and NK cells. While a small population of endogenous CD7(–) T cells exists, these cells are unlikely to be able to repopulate the entir...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Miriam Y., Cooper, Matthew L., Jacobs, Miriam T., Ritchey, Julie K., Hollaway, Julia, Fehniger, Todd A., DiPersio, John F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410010/ https://www.ncbi.nlm.nih.gov/pubmed/34423790 http://dx.doi.org/10.1172/jci.insight.149819

Ejemplares similares

An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies
por: Xiang, Jingyu, et al.
Publicado: (2023)

Selective targeting of histone modification fails to prevent graft versus host disease after hematopoietic cell transplantation
por: Alahmari, Bader, et al.
Publicado: (2018)

A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity
por: Kim, Miriam Y., et al.
Publicado: (2022)

Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc
por: O’Neal, Julie, et al.
Publicado: (2023)

CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells
por: O’Neal, Julie, et al.
Publicado: (2022)

Hematopoeitic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?
por: Goldsmith, Scott R., et al.
Publicado: (2020)

An ‘off-the-shelf’ fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies
por: Cooper, Matthew L., et al.
Publicado: (2018)

Innovations in hematopoietic stem-cell mobilization: a review of the novel CXCR4 inhibitor motixafortide
por: Crees, Zachary D., et al.
Publicado: (2023)

Allogeneic natural killer cell therapy
por: Berrien-Elliott, Melissa M., et al.
Publicado: (2023)

Pharmacologic Blockade of JAK1/JAK2 Reduces GvHD and Preserves the Graft-Versus-Leukemia Effect
por: Choi, Jaebok, et al.
Publicado: (2014)

P1396: CD33-DELETED HEMATOPOIETIC STEM AND PROGENITOR CELLS DISPLAY NORMAL ENGRAFTMENT AFTER HEMATOPOIETIC CELL TRANSPLANT (HCT) AND TOLERATE POST-HCT GEMTUZUMAB OZOGAMICIN (GO) WITHOUT CYTOPENIAS
por: Koehne, Guenther, et al.
Publicado: (2023)

Liposomal phytohemagglutinin: In vivo T‐cell activator as a novel pan‐cancer immunotherapy
por: Alhallak, Kinan, et al.
Publicado: (2022)

Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation
por: Slade, Michael, et al.
Publicado: (2016)

Deletion of Cbl-b inhibits CD8(+) T-cell exhaustion and promotes CAR T-cell function
por: Kumar, Jitendra, et al.
Publicado: (2021)

Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies
por: Liu, Jun, et al.
Publicado: (2017)

P356: PHASE 1/2 DOSE-ESCALATION STUDY OF ANTI-CD7 ALLOGENIC CAR-T CELL IN RELAPSED OR REFRACTORY(R/R) T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC LYMPHOMA(T-ALL/LBL)
por: Ghobadi, Armin, et al.
Publicado: (2023)

Risk for Clostridium difficile Infection After Allogeneic Hematopoietic Cell Transplant Remains Elevated in the Postengraftment Period
por: Dubberke, Erik R., et al.
Publicado: (2017)

HLA Fully-Mismatched Sibling-Derived CD7 CAR-T Therapy Bridging to Haploidentical Hematopoietic Stem Cell Transplantation for Hepatosplenic γδ T-cell Lymphoma
por: Xu, Xueer, et al.
Publicado: (2023)

Large-scale manufacturing and characterization of CMV-CD19CAR T cells
por: Wang, Xiuli, et al.
Publicado: (2022)

Integrin α3β1 Represses Reelin Expression in Breast Cancer Cells to Promote Invasion
por: Ndoye, Abibatou, et al.
Publicado: (2021)

Machine learning–based scoring models to predict hematopoietic stem cell mobilization in allogeneic donors
por: Xiang, Jingyu, et al.
Publicado: (2022)

Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival
por: Hathi, Deep, et al.
Publicado: (2022)

CAR NK-92 cell–mediated depletion of residual TCR(+) cells for ultrapure allogeneic TCR-deleted CAR T-cell products
por: Kath, Jonas, et al.
Publicado: (2023)

Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells
por: Magnani, Chiara F., et al.
Publicado: (2023)

Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells
por: Magnani, Chiara F., et al.
Publicado: (2023)

CD7 CAR: sword and shield
por: Velasquez, M. Paulina, et al.
Publicado: (2022)

A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells
por: Fergusson, Nathan J., et al.
Publicado: (2023)

CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV
por: Kim, Gloria B., et al.
Publicado: (2019)

Beyond adhesion: emerging roles for integrins in control of the tumor microenvironment
por: Longmate, Whitney, et al.
Publicado: (2017)

CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL
por: Fry, Terry J., et al.
Publicado: (2017)

CAR T-Cell Therapy: Is CD28-CAR Heterodimerization Its Achilles’ Heel?
por: Ferreira, Leonardo M. R., et al.
Publicado: (2021)

Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor
por: Crees, Zachary D., et al.
Publicado: (2023)

CD19+ lineage chimerism, an early biomarker after anti-CD19 CAR-T cell therapy in patients previously receiving a hematopoietic stem cell transplantation
por: Martínez-Romera, Isabel, et al.
Publicado: (2022)

CAR T Cell Toxicity: Current Management and Future Directions
por: Yáñez, Lucrecia, et al.
Publicado: (2019)

CD34(+)-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy
por: Mullanfiroze, Khushnuma, et al.
Publicado: (2022)

Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy
por: Urak, Ryan, et al.
Publicado: (2017)

CLRM-10. THE INTER-RELATIONSHIP BETWEEN MULTI-MODAL LONGITUDINAL BIOMARKERS OF NEURAL DAMAGE, INFLAMMATION, AND COGNITION AFTER CAR T CELLULAR THERAPY: A SINGLE-CENTER PROSPECTIVE OBSERVATIONAL TRIAL (NCT04614987)
por: Butt, Omar, et al.
Publicado: (2021)

Mouse models of graft-versus-host disease: advances and limitations
por: Schroeder, Mark A., et al.
Publicado: (2011)

Cav-1 deletion impaired hematopoietic stem cell function
por: Bai, L, et al.
Publicado: (2014)

Immune Adjuvant Therapy With Interleukin-7 in a Lymphopenic Patient With Aplastic Anemia and Mucormycosis
por: Crees, Zachary D., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9u9qjve94dmgouiifm0htfrt9q